147 related articles for article (PubMed ID: 16924148)
1. Human immunodeficiency virus-type 1 specific cellular immunity in chronic infected patients on prolonged highly active antiretroviral treatment and on structured treatment interruption.
Matsuda R; Boström AC; Fredriksson M; Fredriksson EL; Bratt G; Hejdeman B; Sandström E; Okuda K; Wahren B
Microbiol Immunol; 2006; 50(8):629-35. PubMed ID: 16924148
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.
Fu TM; Dubey SA; Mehrotra DV; Freed DC; Trigona WL; Adams-Muhler L; Clair JH; Evans TG; Steigbigel R; Jacobson JM; Goepfert PA; Mulligan MJ; Kalams SA; Rinaldo C; Zhu L; Cox KS; Guan L; Long R; Persaud N; Caulfield MJ; Sadoff JC; Emini EA; Thaler S; Shiver JW
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):67-76. PubMed ID: 17263635
[TBL] [Abstract][Full Text] [Related]
3. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
[TBL] [Abstract][Full Text] [Related]
5. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
[TBL] [Abstract][Full Text] [Related]
6. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
[TBL] [Abstract][Full Text] [Related]
7. HIV-specific immunity during structured antiviral drug treatment interruption.
Moss RB; Brandt C; Giermakowska WK; Savary JR; Theofan G; Zanetti M; Carlo DJ; Wallace MR
Vaccine; 2003 Mar; 21(11-12):1066-71. PubMed ID: 12559781
[TBL] [Abstract][Full Text] [Related]
8. An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects.
D'Offizi G; Gioia C; Corpolongo A; Martini F; Paganelli R; Volpi I; Sacchi A; Tozzi V; Narciso P; Poccia F
Int J Immunopathol Pharmacol; 2007; 20(3):473-85. PubMed ID: 17880761
[TBL] [Abstract][Full Text] [Related]
9. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
[TBL] [Abstract][Full Text] [Related]
10. Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine.
Benito JM; López M; Ballesteros C; Lozano S; Capa L; Barreiro P; Sempere J; Gonzalez-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):734-43. PubMed ID: 16910828
[TBL] [Abstract][Full Text] [Related]
11. HIV-1-infected individuals in antiretroviral therapy react specifically with polyfunctional T-cell responses to Gag p24.
Brandt L; Benfield T; Kronborg G; Gerstoft J; Fomsgaard A; Karlsson I
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):418-27. PubMed ID: 23507659
[TBL] [Abstract][Full Text] [Related]
12. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
Plana M; Garcia F; Oxenius A; Ortiz GM; Lopez A; Cruceta A; Mestre G; Fumero E; Fagard C; Sambeat MA; Segura F; Miró JM; Arnedo M; Lopalcos L; Pumarola T; Hirschel B; Phillips RE; Nixon DF; Gallart T; Gatell JM
J Acquir Immune Defic Syndr; 2004 Jul; 36(3):791-9. PubMed ID: 15213562
[TBL] [Abstract][Full Text] [Related]
13. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.
Schüpbach J; Günthard H; Joos B; Fischer M; Böni J; Tomasik Z; Yerly S; Perrin L; Battegay M; Furrer H; Vernazza P; Bernasconi E; Hirschel B;
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):250-6. PubMed ID: 16249697
[TBL] [Abstract][Full Text] [Related]
15. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
Ortiz GM; Wellons M; Brancato J; Vo HT; Zinn RL; Clarkson DE; Van Loon K; Bonhoeffer S; Miralles GD; Montefiori D; Bartlett JA; Nixon DF
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13288-93. PubMed ID: 11687611
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients.
Libois A; López A; Garcia F; Castro P; Maleno MJ; García A; Climent N; Arnedo M; Gallart T; Gatell JM; Plana M
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):657-66. PubMed ID: 16831090
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy.
Pohling J; Zipperlen K; Hollett NA; Gallant ME; Grant MD
BMC Infect Dis; 2010 May; 10():129. PubMed ID: 20500844
[TBL] [Abstract][Full Text] [Related]
19. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
Ruiz L; Carcelain G; Martínez-Picado J; Frost S; Marfil S; Paredes R; Romeu J; Ferrer E; Morales-Lopetegi K; Autran B; Clotet B
AIDS; 2001 Jun; 15(9):F19-27. PubMed ID: 11416734
[TBL] [Abstract][Full Text] [Related]
20. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
J Virol; 2001 Jan; 75(1):234-41. PubMed ID: 11119593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
